TEHRAN, Sep. 08 (MNA) – Deputy health minister has reported on the entry of home-made Hepatitis C drug to the country’s pharmaceutical market next week noting that it has been produced by Iranian knowledge-based companies.
“The Sofosbuvir drug is used to treat hepatitis C cases; previously it was imported from other countries and priced at $100 per tablet but the indigenous version will be available at the price of 10 dollars per tablet,” said Reza Malekzadeh at a press conference on knowledge-based companies reminding that, “in terms of quality, this drug fully complies with foreign ones and there is no difference in terms of efficiency or treatment of the disease.”
He also reported the production of two other combination drugs to treat hepatitis C in the country adding that they are currently at laboratory stage and will soon be released. “There are now drugs that can treat hepatitis C and there exists the possibility of eradication of the hepatitis C virus in the country in near future; hepatitis C has a three-month course of treatment and patients should take one tablet per day for full treatment,” added Malekzadeh.
Read more...
Tuesday, September 8, 2015
Medicines Patent Pool looks at hepatitis C
Greg Perry, Executive Director of the Medicines Patent Pool, told delegates at the World Hepatitis Summit in Glasgow this week that the organisation was considering how it could act to speed up and expand access to direct-acting antivirals for lower- and middle-income countries, where around 85% of people with hepatitis C are estimated to live.
The Medicines Patent Pool was established with the support of UNITAID, the international drug and diagnostics purchase fund for HIV, tuberculosis and malaria, to negotiate voluntary licensing agreements with pharmaceutical companies that would allow widespread access to low-cost antiretroviral drugs for HIV treatment. The Medicines Patent Pool was also designed as a mechanism to overcome barriers to the development of fixed-dose drug combinations of products from more than one manufacturer, for efficient delivery of treatment in lower- and middle-income countries.
Since its launch in 2010 the Medicines Patent Pool has negotiated voluntary licensing agreements with all the major pharmaceutical companies that allow some or all of their antiretroviral products to be copied by generic manufacturers for sale at greatly reduced prices in lower- and middle-income countries.
Read more...
The Medicines Patent Pool was established with the support of UNITAID, the international drug and diagnostics purchase fund for HIV, tuberculosis and malaria, to negotiate voluntary licensing agreements with pharmaceutical companies that would allow widespread access to low-cost antiretroviral drugs for HIV treatment. The Medicines Patent Pool was also designed as a mechanism to overcome barriers to the development of fixed-dose drug combinations of products from more than one manufacturer, for efficient delivery of treatment in lower- and middle-income countries.
Since its launch in 2010 the Medicines Patent Pool has negotiated voluntary licensing agreements with all the major pharmaceutical companies that allow some or all of their antiretroviral products to be copied by generic manufacturers for sale at greatly reduced prices in lower- and middle-income countries.
Read more...
Study’s Findings Could Help Expand the Donor Pool for Liver Transplantation
Organ donation after circulatory death (DCD), in which transplant organs are taken from donors after ay period of no blood circulation or oxygenation, is often considered inferior to donation after brain death, in which circulation and oxygenation are maintained until organs are removed for transplantation. Currently, the use of livers from DCD donors remains controversial, particularly with donors with advanced age.
A new study of DCD liver transplantations conducted at the Cleveland Clinic from 2005 to 2014 found no significant correlation between donor age and organ survival, however. The results suggest that stringent donor and recipient selection may ameliorate the negative impact of donor age in DCD liver transplantation.
“Aged DCD organs are generally underutilized by many transplant surgeons because of the higher risk of transplant organ failure; however, by eliminating other risk factors, aged DCD organs can greatly help expand the donor pool for life-saving liver transplantation,” said Dr. Koji Hashimoto, co-author of the Liver Transplantation study.
Source: http://ca.wiley.com/WileyCDA/PressRelease/pressReleaseId-120486.html
A new study of DCD liver transplantations conducted at the Cleveland Clinic from 2005 to 2014 found no significant correlation between donor age and organ survival, however. The results suggest that stringent donor and recipient selection may ameliorate the negative impact of donor age in DCD liver transplantation.
“Aged DCD organs are generally underutilized by many transplant surgeons because of the higher risk of transplant organ failure; however, by eliminating other risk factors, aged DCD organs can greatly help expand the donor pool for life-saving liver transplantation,” said Dr. Koji Hashimoto, co-author of the Liver Transplantation study.
Source: http://ca.wiley.com/WileyCDA/PressRelease/pressReleaseId-120486.html
Monday, September 7, 2015
What’s behind Hepatitis C increase in Franklin County?
GREENFIELD — As Hepatitis C rates have risen sharply in Franklin County, neighboring Hampshire County has seen a slower trend and a lower rate, tempered perhaps by prevention efforts.
Franklin County’s rate of 131 newly discovered Hepatitis C cases per 100,000 residents in 2014 was just under the statewide rate of 134, while Hampshire County trailed with a rate of 73. This is a population-adjusted measure, using numbers collected by the Mass. Department of Public Health. In simple numbers, Franklin County had 94 new cases in 2014 and Hampshire County 116.
Greenfield saw 40 newly discovered cases of the blood-borne liver disease in 2014, while its larger sister to the south saw 29. Northampton’s population of 28,549 at the last census outnumbered Greenfield 3 to 2.
Read more....
Franklin County’s rate of 131 newly discovered Hepatitis C cases per 100,000 residents in 2014 was just under the statewide rate of 134, while Hampshire County trailed with a rate of 73. This is a population-adjusted measure, using numbers collected by the Mass. Department of Public Health. In simple numbers, Franklin County had 94 new cases in 2014 and Hampshire County 116.
Greenfield saw 40 newly discovered cases of the blood-borne liver disease in 2014, while its larger sister to the south saw 29. Northampton’s population of 28,549 at the last census outnumbered Greenfield 3 to 2.
Read more....
Sunday, September 6, 2015
Australia: Region has third highest hepatitis C numbers in NSW
"Only an estimated 1.7% of the population living with the blood-borne virus have accessed treatment."
THE Northern Rivers continues to have one of the highest number of hepatitis C cases in the state with 233 new notifications last year.
Figures from the NSW Hepatitis B and C Strategies 2014 annual data report rank the Northern NSW Local Health District third in the state with 79 hepatitis C notifications per 100,000 people.
Northern NSW Local Health District HIV and related programs manager Jenny Heslop said most of the 233 people notified had likely been living with hepatitis C for many years.
Read more...
Saturday, September 5, 2015
Anger at hepatitis C trial with call for money to be spent on cures
A MEDICAL trial to teach hepatitis C sufferers how to avoid infecting their children with the virus has been criticised as fearmongering and a waste of desperately needed health funding.
The State Government will partly fund the trial, called Families Living Healthily with hepatitis C, which aims to teach sufferers how to better prevent transmission of the bloodborne virus.
More than 5000 Tasmanians have been diagnosed with hep C, but medical experts believe many more people unknowingly carry the liver-destroying virus in their blood.
Read more....
Friday, September 4, 2015
Diabetes and Fatty Liver Associated with Further Liver Problems--- Adding liver fibrosis to the long list of diabetic complications under consideration...
A recent study published in Hepatology evaluated various risk factors for liver fibrosis in a Dutch population. The call for concern is the prevalence of liver fibrosis in a patient population with low prevalence of hepatitis—the usual suspect of causation.
Some links have shown non-alcoholic liver disease has a connection to liver fibrosis. Certainly, identifying modifiable risk factors and their impact in developing liver problems can be important to targeting change.
The prospective cohort study was conducted over two years in Rotterdam on 3,041 patients, 45 years or older. Abdominal ultrasounds were used to scan their livers and evaluate liver stiffness to characterize potential fibrosis. Further collections of blood, anthropometric measures, medical history, demographics, drug use, alcohol consumption, smoking history and comorbidities were evaluated.
Just over one-third (35.5%) of the patients had the presence of fatty liver and 5.6% of the patients had a liver stiffness over 8 kPa or clinically relevant for liver fibrosis. Not surprisingly, having the presence of positive surface antigens for hepatitis B or C resulted in a five-fold increased chance in also having liver fibrosis
Read more.....
Some links have shown non-alcoholic liver disease has a connection to liver fibrosis. Certainly, identifying modifiable risk factors and their impact in developing liver problems can be important to targeting change.
The prospective cohort study was conducted over two years in Rotterdam on 3,041 patients, 45 years or older. Abdominal ultrasounds were used to scan their livers and evaluate liver stiffness to characterize potential fibrosis. Further collections of blood, anthropometric measures, medical history, demographics, drug use, alcohol consumption, smoking history and comorbidities were evaluated.
Just over one-third (35.5%) of the patients had the presence of fatty liver and 5.6% of the patients had a liver stiffness over 8 kPa or clinically relevant for liver fibrosis. Not surprisingly, having the presence of positive surface antigens for hepatitis B or C resulted in a five-fold increased chance in also having liver fibrosis
Read more.....
Subscribe to:
Posts (Atom)